Treatment and outcome are influenced by various parameters, including tumor size, nodal involvement, grade, estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2) statuses, as well as Ki67 percentage and the presence of angiolymphatic invasion [1–8]. This evidence concerns the gene PGR and neoplasm.